Acta Neuropathologica Communications (Dec 2018)
Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors
- Kohei Fukuoka,
- Yonehiro Kanemura,
- Tomoko Shofuda,
- Shintaro Fukushima,
- Satoshi Yamashita,
- Daichi Narushima,
- Mamoru Kato,
- Mai Honda-Kitahara,
- Hitoshi Ichikawa,
- Takashi Kohno,
- Atsushi Sasaki,
- Junko Hirato,
- Takanori Hirose,
- Takashi Komori,
- Kaishi Satomi,
- Akihiko Yoshida,
- Kai Yamasaki,
- Yoshiko Nakano,
- Ai Takada,
- Taishi Nakamura,
- Hirokazu Takami,
- Yuko Matsushita,
- Tomonari Suzuki,
- Hideo Nakamura,
- Keishi Makino,
- Yukihiko Sonoda,
- Ryuta Saito,
- Teiji Tominaga,
- Yasuhiro Matsusaka,
- Keiichi Kobayashi,
- Motoo Nagane,
- Takuya Furuta,
- Mitsutoshi Nakada,
- Yoshitaka Narita,
- Yuichi Hirose,
- Shigeo Ohba,
- Akira Wada,
- Katsuyoshi Shimizu,
- Kazuhiko Kurozumi,
- Isao Date,
- Junya Fukai,
- Yousuke Miyairi,
- Naoki Kagawa,
- Atsufumi Kawamura,
- Makiko Yoshida,
- Namiko Nishida,
- Takafumi Wataya,
- Masayoshi Yamaoka,
- Naohiro Tsuyuguchi,
- Takehiro Uda,
- Mayu Takahashi,
- Yoshiteru Nakano,
- Takuya Akai,
- Shuichi Izumoto,
- Masahiro Nonaka,
- Kazuhisa Yoshifuji,
- Yoshinori Kodama,
- Masayuki Mano,
- Tatsuya Ozawa,
- Vijay Ramaswamy,
- Michael D. Taylor,
- Toshikazu Ushijima,
- Soichiro Shibui,
- Mami Yamasaki,
- Hajime Arai,
- Hiroaki Sakamoto,
- Ryo Nishikawa,
- Koichi Ichimura,
- on behalf of the Japan Pediatric Molecular Neuro-Oncology Group (JPMNG)
Affiliations
- Kohei Fukuoka
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute
- Yonehiro Kanemura
- Department of Biomedical Research and Innovation, Institute for Clinical Research, Osaka National Hospital, National Hospital Organization|
- Tomoko Shofuda
- Department of Biomedical Research and Innovation, Institute for Clinical Research, Osaka National Hospital, National Hospital Organization|
- Shintaro Fukushima
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute
- Satoshi Yamashita
- Division of Epigenomics, National Cancer Center Research Institute
- Daichi Narushima
- Department of Bioinformatics, National Cancer Center Research Institute
- Mamoru Kato
- Department of Bioinformatics, National Cancer Center Research Institute
- Mai Honda-Kitahara
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute
- Hitoshi Ichikawa
- Department of Clinical Genomics, National Cancer Center Research Institute
- Takashi Kohno
- Division of Genome Biology, National Cancer Center Research Institute
- Atsushi Sasaki
- Department of Pathology, Saitama Medical University
- Junko Hirato
- Department of Pathology, Gunma University Hospital
- Takanori Hirose
- Department of Diagnostic Pathology, Hyogo Cancer Center
- Takashi Komori
- Department of Laboratory Medicine and Pathology (Neuropathology), Tokyo Metropolitan Neurological Hospital
- Kaishi Satomi
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute
- Akihiko Yoshida
- Department of Pathology and Clinical Laboratories, National Cancer Center Hospital
- Kai Yamasaki
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute
- Yoshiko Nakano
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute
- Ai Takada
- Department of Biomedical Research and Innovation, Institute for Clinical Research, Osaka National Hospital, National Hospital Organization|
- Taishi Nakamura
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute
- Hirokazu Takami
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute
- Yuko Matsushita
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute
- Tomonari Suzuki
- Department of Neuro-Oncology/Neurosurgery, Saitama Medical University International Medical Center
- Hideo Nakamura
- Department of Neurosurgery, Kurume University School of Medicine
- Keishi Makino
- Department of Neurosurgery, Faculty of Life Sciences, Kumamoto University Graduate School
- Yukihiko Sonoda
- Department of Neurosurgery, Yamagata University School of Medicine
- Ryuta Saito
- Department of Neurosurgery, Tohoku University Graduate School of Medicine
- Teiji Tominaga
- Department of Neurosurgery, Tohoku University Graduate School of Medicine
- Yasuhiro Matsusaka
- Department of Pediatric Neurosurgery, Osaka City General Hospital
- Keiichi Kobayashi
- Department of Neurosurgery, Kyorin University Faculty of Medicine
- Motoo Nagane
- Department of Neurosurgery, Kyorin University Faculty of Medicine
- Takuya Furuta
- Department of Neurosurgery, Graduate School of Medical Sciences, Kanazawa University
- Mitsutoshi Nakada
- Department of Neurosurgery, Graduate School of Medical Sciences, Kanazawa University
- Yoshitaka Narita
- Department of Neurosurgery and Neurooncology, National Cancer Center Hospital
- Yuichi Hirose
- Department of Neurosurgery, Fujita Health University
- Shigeo Ohba
- Department of Neurosurgery, Fujita Health University
- Akira Wada
- Department of Neurosurgery, Showa University School of Medicine
- Katsuyoshi Shimizu
- Department of Neurosurgery, Showa University School of Medicine
- Kazuhiko Kurozumi
- Department of Neurological Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
- Isao Date
- Department of Neurological Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine
- Junya Fukai
- Department of Neurological Surgery, Wakayama Medical University
- Yousuke Miyairi
- Department of Neurosurgery, Nagano Children’s Hospital
- Naoki Kagawa
- Department of Neurosurgery, Osaka University Graduate School of Medicine
- Atsufumi Kawamura
- Department of Neurosurgery, Hyogo Prefectural Kobe Children’s Hospital
- Makiko Yoshida
- Department of Pathology, Hyogo Prefectural Kobe Children’s Hospital
- Namiko Nishida
- Department of Neurosurgery, Tazuke Kofukai Foundation, Medical Research Institute and Kitano Hospital
- Takafumi Wataya
- Department of Neurosurgery, Shizuoka Children’s Hospital
- Masayoshi Yamaoka
- Department of Pediatrics, The Jikei University School of Medicine
- Naohiro Tsuyuguchi
- Department of Neurosurgery, Osaka University Graduate School of Medicine
- Takehiro Uda
- Department of Neurosurgery, Osaka University Graduate School of Medicine
- Mayu Takahashi
- Department of Neurosurgery, University of Occupational and Environmental Health
- Yoshiteru Nakano
- Department of Neurosurgery, University of Occupational and Environmental Health
- Takuya Akai
- Department of Neurosurgery, Kanazawa Medical University
- Shuichi Izumoto
- Department of Neurosurgery, Faculty of Medicine, Kinki University
- Masahiro Nonaka
- Department of Neurosurgery, Kansai Medical University
- Kazuhisa Yoshifuji
- Department of Neurosurgery, Hokkaido Medical Center for Child Health and Rehabilitation
- Yoshinori Kodama
- Department of Pathology and Applied Neurobiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine
- Masayuki Mano
- Department of Pathology, Osaka National Hospital, National Hospital Organization
- Tatsuya Ozawa
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute
- Vijay Ramaswamy
- Developmental & Stem Cell Biology Program, The Hospital for Sick Children
- Michael D. Taylor
- Developmental & Stem Cell Biology Program, The Hospital for Sick Children
- Toshikazu Ushijima
- Division of Epigenomics, National Cancer Center Research Institute
- Soichiro Shibui
- Department of Neurosurgery, Teikyo University Hospital
- Mami Yamasaki
- Department of Pediatric Neurosurgery, Takatsuki General Hospital
- Hajime Arai
- Department of Neurosurgery, Juntendo University
- Hiroaki Sakamoto
- Department of Pediatric Neurosurgery, Osaka City General Hospital
- Ryo Nishikawa
- Department of Neuro-Oncology/Neurosurgery, Saitama Medical University International Medical Center
- Koichi Ichimura
- Division of Brain Tumor Translational Research, National Cancer Center Research Institute
- on behalf of the Japan Pediatric Molecular Neuro-Oncology Group (JPMNG)
- DOI
- https://doi.org/10.1186/s40478-018-0630-1
- Journal volume & issue
-
Vol. 6,
no. 1
pp. 1 – 18
Abstract
Abstract Extensive molecular analyses of ependymal tumors have revealed that supratentorial and posterior fossa ependymomas have distinct molecular profiles and are likely to be different diseases. The presence of C11orf95-RELA fusion genes in a subset of supratentorial ependymomas (ST-EPN) indicated the existence of molecular subgroups. However, the pathogenesis of RELA fusion-negative ependymomas remains elusive. To investigate the molecular pathogenesis of these tumors and validate the molecular classification of ependymal tumors, we conducted thorough molecular analyses of 113 locally diagnosed ependymal tumors from 107 patients in the Japan Pediatric Molecular Neuro-Oncology Group. All tumors were histopathologically reviewed and 12 tumors were re-classified as non-ependymomas. A combination of RT-PCR, FISH, and RNA sequencing identified RELA fusion in 19 of 29 histologically verified ST-EPN cases, whereas another case was diagnosed as ependymoma RELA fusion-positive via the methylation classifier (68.9%). Among the 9 RELA fusion-negative ST-EPN cases, either the YAP1 fusion, BCOR tandem duplication, EP300-BCORL1 fusion, or FOXO1-STK24 fusion was detected in single cases. Methylation classification did not identify a consistent molecular class within this group. Genome-wide methylation profiling successfully sub-classified posterior fossa ependymoma (PF-EPN) into PF-EPN-A (PFA) and PF-EPN-B (PFB). A multivariate analysis using Cox regression confirmed that PFA was the sole molecular marker which was independently associated with patient survival. A clinically applicable pyrosequencing assay was developed to determine the PFB subgroup with 100% specificity using the methylation status of 3 genes, CRIP1, DRD4 and LBX2. Our results emphasized the significance of molecular classification in the diagnosis of ependymomas. RELA fusion-negative ST-EPN appear to be a heterogeneous group of tumors that do not fall into any of the existing molecular subgroups and are unlikely to form a single category.
Keywords